Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4506935
Author(s) Studerus, Erich; Kometer, Michael; Hasler, Felix; Vollenweider, Franz X.
Author(s) at UniBasel Studerus, Erich
Year 2011
Title Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Journal Journal of Psychopharmacology
Volume 25
Number 11
Pages / Article-Number 1434-52
Mesh terms Adult; Affect, drug effects; Double-Blind Method; Female; Follow-Up Studies; Hallucinogens, adverse effects, pharmacology; Humans; Male; Middle Aged; Perception, drug effects; Psilocybin, adverse effects, pharmacology; Surveys and Questionnaires; Young Adult
Abstract Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1-4 oral doses of psilocybin (45-315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.
Publisher SAGE Publications
ISSN/ISBN 0269-8811 ; 1461-7285
edoc-URL https://edoc.unibas.ch/70607/
Full Text on edoc No
Digital Object Identifier DOI 10.1177/0269881110382466
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20855349
ISI-Number WOS:000297943900002
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.348 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
26/04/2024